StageZero Life Sciences (STU:61N1) Cyclically Adjusted Book per Share: €-0.09 (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:61N1 StageZero Life Sciences Ltd STU:61N1
10 GF Score
Price €0.02
View Full Analysis

What is StageZero Life Sciences Cyclically Adjusted Book per Share?

StageZero Life Sciences STU:61N1 10 Cyclically Adjusted Book per Share is €-0.09 as of Sep. 2024. GuruFocus rates STU:61N1 with a GF Score™ of 10/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

StageZero Life Sciences's adjusted book value per share for the three months ended in Sep. 2024 was €-0.081. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €-0.09 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-25), StageZero Life Sciences's current stock price is €0.0155. StageZero Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was €-0.09. StageZero Life Sciences's Cyclically Adjusted PB Ratio of today is .


StageZero Life Sciences  (STU:61N1) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


StageZero Life Sciences Cyclically Adjusted Book per Share Related Terms


StageZero Life Sciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for StageZero Life Sciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StageZero Life Sciences Cyclically Adjusted Book per Share Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.10 -0.09

StageZero Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.13 -0.12 -0.09 -0.09

STU:61N1 vs IDTA, TTOO, NSTM: Cyclically Adjusted Book per Share Comparison

For the Diagnostics & Research subindustry, StageZero Life Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StageZero Life Sciences Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's Cyclically Adjusted PB Ratio falls into.


STU:61N1
10GF Score
StageZero Life Sciences Ltd STU:61N1
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StageZero Life Sciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, StageZero Life Sciences's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book= Book Value per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.081/127.2847*127.2847
=-0.081

Current CPI (Sep. 2024) = 127.2847.

StageZero Life Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201409 0.506 99.394 0.648
201412 0.274 98.367 0.355
201503 0.326 99.789 0.416
201506 0.166 100.500 0.210
201509 -0.004 100.421 -0.005
201512 -0.233 99.947 -0.297
201603 -0.483 101.054 -0.608
201606 -0.565 102.002 -0.705
201609 -0.613 101.765 -0.767
201612 -0.439 101.449 -0.551
201703 -0.438 102.634 -0.543
201706 -0.320 103.029 -0.395
201709 -0.244 103.345 -0.301
201712 -0.214 103.345 -0.264
201803 -0.157 105.004 -0.190
201806 -0.220 105.557 -0.265
201809 -0.247 105.636 -0.298
201812 -0.252 105.399 -0.304
201903 -0.400 106.979 -0.476
201906 -0.329 107.690 -0.389
201909 -0.149 107.611 -0.176
201912 -0.119 107.769 -0.141
202003 -0.150 107.927 -0.177
202006 -0.071 108.401 -0.083
202009 -0.140 108.164 -0.165
202012 -0.017 108.559 -0.020
202103 -0.058 110.298 -0.067
202106 0.006 111.720 0.007
202109 0.039 112.905 0.044
202112 0.027 113.774 0.030
202203 0.026 117.646 0.028
202206 0.014 120.806 0.015
202209 0.014 120.648 0.015
202212 -0.067 120.964 -0.071
202303 -0.079 122.702 -0.082
202306 -0.063 124.203 -0.065
202309 -0.069 125.230 -0.070
202403 -0.076 126.258 -0.077
202406 -0.081 127.522 -0.081
202409 -0.081 127.285 -0.081

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €-0.09 mean?
StageZero Life Sciences (STU:61N1) has a Cyclically Adjusted Book per Share of €-0.09 as of Sep. 2024. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on StageZero Life Sciences and its competitors.
Is StageZero Life Sciences' Cyclically Adjusted Book per Share too high?
StageZero Life Sciences' current Cyclically Adjusted Book per Share is €-0.09. Overall, StageZero Life Sciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does StageZero Life Sciences' Cyclically Adjusted Book per Share compare to IDTA and TTOO?
StageZero Life Sciences' Cyclically Adjusted Book per Share of €-0.09 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Book per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on StageZero Life Sciences and its competitors. StageZero Life Sciences's current Cyclically Adjusted Book per Share is €-0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StageZero Life Sciences stock overvalued right now?
StageZero Life Sciences (STU:61N1) has a current Cyclically Adjusted Book per Share of €-0.09. The current Cyclically Adjusted Book per Share is €-0.09. StageZero Life Sciences' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For StageZero Life Sciences (STU:61N1), the current Cyclically Adjusted Book per Share is €-0.09 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StageZero Life Sciences Business Description

Address 70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score

Get the complete analysis for STU:61N1

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price